📰 Prime Editing News
Page 3 - Prime Editing News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Prime Editing. Real-time updates on events, politics, business and more.
October 24, 2023
New In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at...
September 18, 2023
This article seeks to illuminate these pioneering developments and their potential impact on future scientific endeavors of biotechnology and genetics
August 10, 2023
MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic partnership with Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies.
August 1, 2023
Prime Medicine to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance their innovative Prime Editing technology and develop a...
July 31, 2023
LOS ANGELES, July 31, 2023 (GLOBE NEWSWIRE) -- Solve GNE, a Los Angeles based non-profit organization, has raised over $2.5 million and negotiated...
June 22, 2023
-- Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimens and introduce new therap...
May 17, 2023
CAMBRIDGE, Mass., May 17, 2023 -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that... | May 17, 2023
October 20, 2022
Prime Medicine has yet to test prime editing in humans, but the biotech company garnered enough investor interest to boost the size of its IPO, raising $175 million. Prime claims its technology has key advantages over other gene-editing technologies and the IPO cash will support a pipeline that currently spans 18 programs.
June 2, 2022
The pharma giant wants to repair genes with its own technology as a way to cure diseases, AstraZeneca's Steve Rees told Insider.